You are here

Our science / Clinical Trials / Find a Trial / NCT00828919

Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

Back to Search Print Save as PDF Bookmark Trial

NCT00828919

Last updated on April 13, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
UC Irvine Medical Center
Orange, California, 92868 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who were assigned to an axitinib containing treatment arm in a previous
clinical trial

- Patients who were receiving axitinib tablets at the time their previous trial ended

- Patients who have stable (SD) or responding disease (PR or CR) documented by the
appropriate radiological, clinical, or laboratory assessments within 12 weeks before
enrollment (Note: response criteria from the previous AG-013736 protocol should be
used to determine stable or responding disease).

- Patients who have progressive disease (PD) but have experienced "clinical benefit" as
defined in the study protocol

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients may not participate in this trial if the conditions for continuing treatment
in the previous AG-013736 protocol are not met

NCT00828919
Pfizer
Active, not recruiting
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
NCT02573259
All Genders
18+
Years
Multiple Sites
Solid Tumors
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials
NCT00828919
All Genders
0+
Years
Multiple Sites
Advanced Solid Tumors
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
NCT02997163
All Genders
18+
Years
Multiple Sites
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials
Continuing Access To The Tyrosine Kinase Inhibitor Of Vegfr 2, Ag 013736 (a406) For Patients Previously Receiving Ag 013736 In Clinical Trials
To allow continuation of treatment of patients experiencing benefit from AG 013736
Not Provided
Interventional
Not Provided
Masking: None (Open Label)
Primary Purpose: Treatment
Solid Tumors
Drug: axitinib
BID oral tablets. dose of AG 013736 will be the same as they were taking in the previous trial
Other Name: AG-013736
axitinib
Intervention: Drug: axitinib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
52
February 2018
February 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who were assigned to an axitinib containing treatment arm in a previous clinical trial
  • Patients who were receiving axitinib tablets at the time their previous trial ended
  • Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous AG-013736 protocol should be used to determine stable or responding disease).
  • Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol

Exclusion Criteria:

  • Patients may not participate in this trial if the conditions for continuing treatment in the previous AG-013736 protocol are not met
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Czechia,   France,   Germany,   Hungary,   Italy,   Japan,   Korea, Republic of,   Russian Federation,   Taiwan,   United Kingdom,   United States
Czech Republic
 
NCT00828919
A4061008
2005-000051-15 ( EudraCT Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now